Discovery of Ertugliflozin (PF-04971729): An overview of the progression of Pfizer’s SGLT2 inhibitor program from discovery to successful POC Read more about Discovery of Ertugliflozin (PF-04971729): An overview of the progression of Pfizer’s SGLT2 inhibitor program from discovery to successful POC
A bispecific antibody targeting kk1 and Sclerostin for patients with delayed fracture healing Read more about A bispecific antibody targeting kk1 and Sclerostin for patients with delayed fracture healing
A bispecific antibody targeting kk1 and Sclerostin for patients with delayed fracture healing Read more about A bispecific antibody targeting kk1 and Sclerostin for patients with delayed fracture healing
The Power of Structure and Physicochemical Property-Based Drug Design. From Bench to the Clinic with Case Studies Read more about The Power of Structure and Physicochemical Property-Based Drug Design. From Bench to the Clinic with Case Studies
Pitfalls and barriers in small molecule drug discovery Read more about Pitfalls and barriers in small molecule drug discovery
Discovery of Novel Nucleotide Prodrug GS-5734 for the Treatment of Ebola Virus disease Read more about Discovery of Novel Nucleotide Prodrug GS-5734 for the Treatment of Ebola Virus disease
Discovery of Ivacafsor, a CFTR Potentiator for the Treatment of Cystic Fybrosis Read more about Discovery of Ivacafsor, a CFTR Potentiator for the Treatment of Cystic Fybrosis